ArticleNature reviews. Methods primers2025
Droplet-based bioprinting.
Article in Nature reviews. Methods primers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- 3D bioprinting of tissues and organs for systemic diseases and localized injuries.Military Medical Research · 2026Review
- AI for bioactive materials: From material design to biological applications.Bioactive materials · 2026Review
- Engineering heterogeneous tissues and organs via multi-material bioprinting: Advances, challenges, and opportunities.Acta biomaterialia · 2026Review
- Advances in 3D Bioprinting for Scaffold-Based and Scaffold-Free Tissue Engineering and Regenerative Medicine.Gels (Basel, Switzerland) · 2026Review
- Tissue-bioelectronics interfaces.Chemical Society reviews · 2026Review
- A toolbox for microvalve-based bioprinting.Biofabrication · 2026Article
- The Role of 3D Printing in Regenerative Medicine: A Game-Changer in Tissue Engineering.International journal of molecular sciences · 2026Review
- Unconventional bioprinting modalities for advanced tissue biofabrication.Biomaterials · 2026Review
- Three-tier framework for high-throughput biofabrication: Integrating 3D bioprinting, assistive platforms, and translational opportunities.Bioactive materials · 2026Review
- Liquid-in-Liquid Prints: High-Density Biochemically Encoded Information Preserved in Microdroplet Arrays.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Self-driving bioprinting laboratories.Biofabrication · 2026Review
- Progressive Insights into 3D Bioprinting for Corneal Tissue Restoration.Advanced healthcare materials · 2026Review
- Surface Energy-Confined Multi-Layer Inkjet Printing for Customizable Optical Microstructures.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Recent Advances in Periodontal Regenerative Medicine: A Focus on the Role of Mechanical Stimulation.Biomedicines · 2025Review
- Rheological, Structural, and Biological Trade-Offs in Bioink Design for 3D Bioprinting.Gels (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Three-dimensional (3D) bioprinting facilitates the automated patterning of biological entities (such as cells and tissue building blocks) with or without scaffolding biomaterials. The technique enables fabrication of highly organized structures that recapitulate the physiological and biological functions of native tissues. Droplet-based bioprinting (DBB) is unique among the existing bioprinting modalities in its ability to handle and manipulate bioprinting at the cellular level, as well as to develop complex 3D constructs in a high-throughput manner. As an evolving bioprinting modality, DBB has greatly advanced our understanding of cell interactions, tissue and organ formation, and human disease. This Primer gives an overview of the methodology of DBB, detailing its various modalities and its associated hardware and software, including the selection of bioinks and substrates, as well as their interactions and compatibility with different DBB sub-modalities. Finally, recent advances and several limitations of DBB are summarized and considerations are discussed for potential improvements to the technology in the future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.